Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse

用于药物滥用的新型神经元 nAChR 沉默脱敏剂的设计与合成

基本信息

  • 批准号:
    7574184
  • 负责人:
  • 金额:
    $ 19.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-02-01 至 2011-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): To address the devastating effects of drug addiction, this project aims to deliver three potential drug candidates for further development and eventual clinical application. Drugs of abuse have differing mechanisms of action, but share a common pathway toward physical dependency. The mesolimbic dopamine pathway is widely accepted as a central pathway in producing the rewarding effects of addictive drugs. This pathway includes the dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and their targets in the limbic forebrain, especially the nucleus accumbens (NAc). All drugs of abuse, regardless of their mechanisms of actions, converge on the VTA-NAc pathway. Acute exposure to addictive drugs results in the elevation of dopamine levels, a reward signaling event, which promotes repeated drug intake. Addiction is then reinforced by the drugs producing a negative emotional symptom when the drug is removed. Sensitization and associative learning toward drug-related environmental cues also reinforce addiction. The nicotinic cholinergic receptors (nAChRs) may be an important target for the treatment of multiple addictions, not just nicotine. Activation of the central nAChRs has been shown to also mediate the reinforcing effects of other drugs of abuse including alcohol and cocaine. The 1422 subtype of nicotinic cholinergic receptors are implicated in the addictive properties of nicotine. Nicotine is an agonist of nAChRs, and has a dual mode of activation and desensitization. Until recently, these two modes of activation and desensitization could not be decoupled. Sazetidine A, a novel small molecule ligand of nAChR, does just this, selectively desensitizes 1422 receptors without first activating them. Preliminary data suggest that this molecule may indeed prove to be an interesting drug for treating addiction. Unfortunately, sazetidine A has poor physicochemical properties for further drug development. Sazetidine A has a relatively low log P value, a high polar surface area (PSA) value, and is a viscous oil. The low log P and high PSA suggest sazetidine A will not be readily absorbed in vivo and will have a low probability of crossing the blood-brain barrier. The lack of crystallinity poses problems in manufacturing this compound for further drug development. The aims of this proposal are to design and synthesize new 1422-selective desensitizers with the following improved physicochemical properties: 1. optimal log P value between 2 and 5; 2. reduced PSA of approximately 60 E2; and 3. crystallinity with a melting point greater than 150 0C. PUBLIC HEALTH RELEVANCE: Drug addiction is a chronic brain disease with devastating societal impact. Since drug addiction has traditionally been viewed as a social problem, not a health problem, there is a disparity in effective medical treatment options. This proposal is directed at addressing this disparity by providing new therapeutic agents for medical intervention of drug abuse.
描述(由申请人提供):为了解决药物成瘾的破坏性影响,该项目旨在提供三种潜在的候选药物,用于进一步开发和最终的临床应用。药物滥用有不同的作用机制,但有一个共同的途径,以身体依赖。中脑边缘多巴胺通路被广泛认为是成瘾药物产生奖赏效应的中心通路。这条通路包括中脑腹侧被盖区(VTA)的多巴胺能神经元及其在边缘前脑,特别是丘脑核(NAc)的靶点。所有滥用药物,无论其作用机制如何,都集中在VTA-NAc途径上。急性暴露于成瘾性药物导致多巴胺水平升高,这是一种奖励信号事件,促进了重复的药物摄入。当药物被移除时,药物会产生负面的情绪症状,从而加强成瘾。对与毒品有关的环境线索的敏感化和联想学习也会加强成瘾。烟碱胆碱能受体(nAChRs)可能是治疗多种成瘾的重要靶点,而不仅仅是尼古丁。中枢nAChR的激活也被证明介导其他滥用药物(包括酒精和可卡因)的强化作用。烟碱胆碱能受体的1422亚型与尼古丁的成瘾特性有关。尼古丁是nAChR的激动剂,并且具有激活和脱敏的双重模式。直到最近,这两种模式的激活和脱敏不能解耦。氮杂环丁烷A是一种新型的nAChR小分子配体,它可以选择性地使1422种受体脱敏,而不首先激活它们。初步数据表明,这种分子确实可能被证明是一种治疗成瘾的有趣药物。不幸的是,sazetidine A的物理化学性质差,无法进一步开发药物。氮杂环丁烷A具有相对低的log P值、高的极性表面积(PSA)值,并且是粘性油。低log P和高PSA表明沙泽替丁A在体内不易吸收,穿过血脑屏障的可能性较低。结晶度的缺乏在制造用于进一步药物开发的该化合物中造成问题。本论文的目标是设计合成具有以下物理化学性质的新型1422选择性脱敏剂:1。最佳log P值在2和5之间; 2. PSA降低约60 E2;和3.熔点大于150 ℃的结晶度。公共卫生相关性:药物成瘾是一种慢性脑部疾病,具有破坏性的社会影响。由于吸毒成瘾传统上被视为一个社会问题,而不是一个健康问题,因此在有效的医疗选择方面存在差异。该提案旨在通过提供用于药物滥用的医学干预的新治疗剂来解决这种差异。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(6)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIKELL PAIGE其他文献

MIKELL PAIGE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIKELL PAIGE', 18)}}的其他基金

Manufacturing and Characterization of Potent mRNA Lipid Nanoparticle Vaccines at Multiple Scales
多尺度有效 mRNA 脂质纳米颗粒疫苗的制造和表征
  • 批准号:
    10491863
  • 财政年份:
    2021
  • 资助金额:
    $ 19.19万
  • 项目类别:
Manufacturing and Characterization of Potent mRNA Lipid Nanoparticle Vaccines at Multiple Scales
多尺度有效 mRNA 脂质纳米颗粒疫苗的制造和表征
  • 批准号:
    10407326
  • 财政年份:
    2021
  • 资助金额:
    $ 19.19万
  • 项目类别:
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema
CDX-MDM在小鼠肺气肿临床前模型中的应用
  • 批准号:
    8524532
  • 财政年份:
    2013
  • 资助金额:
    $ 19.19万
  • 项目类别:
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse
用于药物滥用的新型神经元 nAChR 沉默脱敏剂的设计与合成
  • 批准号:
    7759556
  • 财政年份:
    2009
  • 资助金额:
    $ 19.19万
  • 项目类别:
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse
用于药物滥用的新型神经元 nAChR 沉默脱敏剂的设计与合成
  • 批准号:
    8083155
  • 财政年份:
    2009
  • 资助金额:
    $ 19.19万
  • 项目类别:
Design and Synthesis of New Neuronal nAChR Silent Desensitizers for Drug Abuse
用于药物滥用的新型神经元 nAChR 沉默脱敏剂的设计与合成
  • 批准号:
    7881878
  • 财政年份:
    2009
  • 资助金额:
    $ 19.19万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了